Fibrocell Reports First Quarter 2017 Financial Results And Recent Operational Highlights

EXTON, Pa., May 10, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today reported financial results for the first quarter ended March 31, 2017 and recent operational highlights. Fibrocell will host a conference call and webcast today at 8:30 a.m. EDT.

“This is an exciting time at Fibrocell as our gene therapy candidates continue to make significant progress that moves us closer to our goal of transforming the lives of patients suffering with rare and debilitating genetic diseases of the skin and connective tissue,” said John Maslowski, Chief Executive Officer of Fibrocell. “We look forward to safety and efficacy data in the third quarter of 2017 from the first cohort of patients in the Phase 1/2 study of FCX-007, our product candidate for the treatment of recessive dystrophic epidermolysis bullosa.”

Back to news